Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Jul 30;383(5):498-500.
doi: 10.1056/NEJMc2005943.

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

Inhye E Ahn  1 , Xin Tian  1 , Adrian Wiestner  1
Affiliations
Clinical Trial

Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations

Inhye E Ahn et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Overall and Progression-free Survival among the Study Patients Receiving Ibrutinib.
Panel A shows Kaplan–Meier estimates of overall survival and progression-free survival among 34 patients with chronic lymphocytic leukemia with TP53 alterations who were treated with ibrutinib as first-line therapy. Tick marks indicate censored data. Panel B shows a summary of survival estimates with the percentage and 95% confidence interval (CI) at each selected time point.
See this image and copyright information in PMC

References

    1. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379:2517–28. - PMC - PubMed
    1. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381:432–43. - PMC - PubMed
    1. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380:2225–36. - PubMed
    1. Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study. Blood 2018;131:2357–66. - PMC - PubMed
    1. O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016;17:1409–18. DOI: 10.1056/NEJMc2005943 - DOI - PubMed

MeSH terms